Abstract Previous studies have identified moderately elevated plasma concentrations of homocyst(e)ine as an independent risk factor for coronary heart disease (CHD). The atherogenicity of homocyst(e)ine has mostly been attributed to its effects on endothelial cells, platelets, and the hemostatic system. In this case-control study of 199 male CHD patients and 156 age-matched control subjects, we analyzed the role of homocyst(e)ine as a cardiovascular risk marker in the context of traditional risk factors as well as of plasma fibrinogen, plasminogen, and viscosity. Both univariate and multivariate regression analyses revealed that homocyst(e)ine levels were significantly correlated with age, fibrinogen, and plasma viscosity in both study groups. Geometric mean homocyst(e)ine levels by univariate analysis were significantly higher in patients than in control subjects (8.9 versus 7.8 ^mol/L, f<.001). This difference re-H omocysteine is a sulfhydryl-containing amino acid formed by demethylation of methionine. It is catabolized to cysteine by the pyridoxal phosphate-dependent enzymes cystathionine /3-synthase and •y-cystathionase. It is also remethylated to methionine through folate-and vitamin B 12 -dependent enzymes and from demethylation of betaine.
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1 -2 Oxidation of homocysteine forms homocysteine disulfide (homocysteine), or homocysteine-cysteine mixed disulfide. The free and protein-bound forms are here referred to as homocyst(e)ine, since our method measures both homocysteine and its oxidation products. 3 -4 Genetic defects in cystathionine /3-synthase or tetrahydrofolate reductase interfere with the transsulfuration or remethylation of homocysteine and are involved in the pathogenesis of homocystinuria. This rare disease is associated with dramatically increased homocyst(e)ine plasma concentrations and premature arteriosclerosis. 1 Furthermore, several case-control studies as well as one nested study have established that moderately elevated homocys-mained significant on multiple logistic function analysis after being adjusted for body mass index, systolic blood pressure, serum cholesterol, and high-density lipoprotein cholesterol but not after additional adjustment for fibrinogen. By contrast, geometric mean fibrinogen levels after adjustment for homocyst(e)ine levels were significantly different between patients and control subjects (296.4 versus 230.8 mg/dL, P<.001). Within the group of CHD patients, both fibrinogen and homocyst(e)ine significantly increased in parallel with the number of stenosed coronary vessels. We conclude that hyperhomocyst(e)inemia is an independent coronary risk factor and that its interrelation with fibrinogen levels merits further study. (Arteriosder Thromb.
1994;14:4<J0-464.)
Key Words • homocysteine • fibrinogen • coronary heart disease • cardiovascular risk factors t(e)ine levels are associated with coronary, cerebrovascular, or peripheral artery disease independently from other coronary risk factors, including age, smoking, hypercholesterolemia, and reduced high-density lipoprotein cholesterol (HDL-C). 2 8 Moreover, hyperhomocyst(e)inemia is found at increased prevalence in patients with arterial hypertension. 3 The atherogenic mechanism of hyperhomocyst(e)inemia is unknown. Homocysteine may interfere with the interaction between platelets and the vascular endothelium, 9 ' 10 or it may damage the endothelium and thereby decrease the production of anti-platelet-aggregatory and antivasoconstrictive substances, including endothelium-derived relaxing factor (nitric oxide) or prostacyclin." The interaction of homocysteine and endothelial cells may also exert procoagulatory effects. In vitro, homocysteine increases the activity of factor V in endothelial cells and decreases the activity of the endothelial thrombin receptor thrombomodulin, thereby decreasing protein C activation.
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Previous clinical studies have examined the role of homocyst(e)ine as a cardiovascular risk factor and its relation to other more traditional risk factors including smoking, hypertension, and dyslipidemia. 28 In the present case-control study, we also explored possible relations between homocyst(e)inemia and certain hemostatic parameters.
Methods

Patients and Samples
lar Munster (PROCAM) study, respectively. 15 Because of the age dependence of homocyst(e)ine levels and because of the different age distribution in the two study groups, we age matched 156 control subjects and 199 patients whose ages ranged between 36 and 65 years.
Venous blood samples were drawn from patients with angiographically diagnosed CHD (at least one vessel being stenosed by 50%) 4 or more weeks after myocardial infarction or aortocoronary bypass surgery. Sera and plasma were obtained within 2 hours after blood sampling by centrifugation for 15 minutes at 2000g and were immediately frozen at -70°C. Hemostatic parameters as well as lipid and homocyst(e)ine levels were measured within 3 months after sample collection. Serum was used for quantification of lipids, lipoproteins, and homocyst(e)ine; citrated plasma was used for the measurement of hemostatic parameters.
Laboratory Methods
Triglycerides and cholesterol were measured with an autoanalyzer (Hitachi/Boehringer Mannheim). HDL-C concentrations were measured after precipitation of apolipoprotein B-containing lipoproteins with phosphotungstic acid/MgCl 2 (Boehringer Mannheim). Low-density lipoprotein cholesterol (LDL-C) was calculated by using the Friedewald formula. 16 Plasma concentrations of fibrinogen were determined according to Clauss 17 ; the plasma activity of plasminogen was measured by using assay kits from Behringwerke. Plasma viscosity was measured by using a microviscosimeter (Haake). Homocyst(e)ine in coded sera samples was determined by highperformance liquid chromatography and electrochemical detection as described. 
Selective Coronary Angiography
Selective coronary angiography was performed by using the technique of Judkins 18 or of Sones 19 if the patients also had peripheral artery disease or contraindications for arterial puncture in the inguinal region. The left coronary artery was examined in several left anterior oblique (LAO) views, including a craniocaudal projection, and two right anterior oblique (RAO) views, including the caudocranial projection. The right coronary artery was projected in at least one LAO and one RAO view. To ensure that all vessel segments were viewed without any overlap, additional projections were recorded according to coronary morphology. Angiograms were recorded on 35-mm cineangiographic film. A coronary artery was considered affected by coronary disease if its diameter was stenosed by at least 50% at any segment as judged by at least two observers.
Statistical Analyses
Statistical analyses were done by using the STATISTICAL PACKAGE FOR THE SOCIAL SCIENCES. All parameters except triglycerides, fibrinogen, and homocysteine are presented as mean±SD. The indicated parameters did not exhibit a gaussian frequency distribution and are therefore presented as geometric means±l SD confidence intervals as obtained by log. retransformation. Since not all variables were normally distributed, nonparametric statistical tests were used when appropriate (ie, Mann-Whitney U test and Spearman rank correlation).
Results
Linear regression analyses in 348 male CHD patients and 188 PROCAM control subjects revealed positive relations between age and homocyst(e)ine levels in both groups (r=.29, /'•c.OOl; not shown in tables). Fibrinogen and cholesterol levels were also significantly correlated with age. Because of these correlations and because of the different frequency distribution of age in the two groups, we selected data from 199 CHD patients and 156 PROCAM control subjects whose ages ranged from 36 to 65 years and who were matched on age by ± 1 year. Baseline coronary risk factor data of these patients are described in Table 1 . Upon univariate analysis, mean values of systolic blood pressure ( + 7%), HDL-C (-23%), LDL-C ( + 10%), fibrinogen (+31%), plasminogen (-16%), viscosity (+4.8%), and homocyst(e)ine ( + 17%) significantly differed in patients and control subjects, respectively (P<.001 by Mann-Whitney U test). The importance of homocyst(e)ine as a marker for CHD also became obvious when its serum concentration was related to the extent of coronary vessel disease: besides fibrinogen, only homocyst(e)ine was significantly associated with the number of stenosed coronary artery vessels (P<.05; Table 2) .
In regression analyses we tested the dependence of homocyst(e)ine levels on age, body mass index, blood pressure, lipids, and hemostatic parameters. Univariate regression analyses revealed that homocyst(e)ine serum concentrations were significantly correlated with age, fibrinogen, and plasma viscosity in both study groups (Table 3) . Fibrinogen was correlated with age, plasminogen, and plasma viscosity in both study groups. Furthermore, fibrinogen was significantly correlated with triglycerides, cholesterol, LDL-C, and diastolic blood pressure in the control group (Table 3) . Multivariate analysis was limited to those parameters that correlated at least in one group with either homocyst(e)ine or fibrinogen. With this restriction, the correlations of homocyst(e)ine with age and of fibrinogen with age and viscosity remained stable (Table 4 ). In contrast, the significant relation between fibrinogen and homocyst(e)ine was lost on multivariate analysis in both groups (Table 4) . Multiple logistic function analysis was used to test the independence of fibrinogen and homocyst(e)ine as predictors of coronary risk. We tested a model in which we considered those parameters that on univariate analysis were significantly different between patients and control subjects (Table 1) , namely homocyst(e)ine, fibrinogen, HDL-C, and systolic blood pressure. Since LDL-C values were not measured but calculated, we also considered cholesterol (Table 5) . Age was not considered in this analysis because patients and control subjects had been matched for age. We did not consider viscosity because of its strong correlation with fibrinogen. Plasminogen was also not taken into consideration because it has not yet been proven as an independent coronary risk factor. In this model homocyst(e)ine was significantly different between patients and control subjects only when fibrinogen was not considered. In contrast, fibrinogen remained significantly different between patients and control subjects even when adjusted for homocyst(e)ine (Table 5 ). Even in a bivariate model that considered only values for fibrinogen and homocyst(e)ine, fibrinogen (standardized estimate, -0.993, / > <.0001) but not homocyst(e)ine (standardized estimate, -0.144, P=.127) was significantly different between patients and control subjects by x 2 test.
Discussion
The present observations as well as other studies 28 demonstrate that mean homocyst(e)ine levels are nearly 20% higher in male CHD patients than in control subjects (Table 1) . Furthermore, we observed a dose effect of homocyst(e)ine on the number of stenosed coronary ves- Table 2 ) that is also reported by Ubbink and colleagues. 20 In the present study similar findings were observed with fibrinogen.
sels (
In this age-matched population and in another study, 7 hyperhomocysteinemia was an independent cardiovascular risk factor after adjustment for the traditional factors of systolic blood pressure, total cholesterol, and HDL-C (Table 5) . This independence disappeared when we considered fibrinogen, which on univariate analysis significantly correlated with homocyst(e)ine in both study groups (Table 3 ) and which was not taken into consideration in previously reported studies. In contrast to homocyst(e)ine, fibrinogen levels were significantly different between patients and control subjects after adjustment for the traditional risk factors as well as for homocyst(e)ine (Table 5) .
Fibrinogen is an acute-phase reactant whose plasma concentration increases after myocardial infarction and remains slightly increased even 1 year thereafter, 21 -22 so that from our case-control study one cannot conclude that fibrinogen is a cardiovascular risk factor. However, since several prospective studies have identified fibrinogen 23 - 28 and plasma viscosity 27 as independent coronary risk factors, our findings may underline the impor- tance of the proaggregatory and procoagulatory effects of homocyst(e)ine that have been deduced from in vitro studies.
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To our knowledge, no population studies have been reported that analyze the relation between homocyst(e)ine and fibrinogen. Harker et al 9 and Munnich et al, 29 however, have investigated this question in patients with homocystinuria and found higher fibrinogen levels in patients compared with control subjects. Harker and colleagues 9 also observed a slightly enhanced turnover of radiolabeled fibrinogen in patients with homocystinuria. Since the increased catabolism did not result in lower fibrinogen levels, one must assume that the enhanced turnover of fibrinogen in homocystinuric patients is balanced by increased production of fibrinogen. From a mechanistic point of view, the positive correlation between homocyst(e)ine and fibrinogen levels is unexpected, since homocyst(e)ine inhibits the expression of thrombomodulin and the activation of protein C.
14 Both interferences should favor the generation of thrombin and thereby the conversion of fibrinogen into fibrin and should therefore decrease fibrinogen levels. Formation of fibrin, however, is accompanied by fibrinolysis and fibrin split-product formation, which in turn stimulate the synthesis of fibrinogen. If the positive correlation between homocyst(e)ine and fibrinogen is causal, one must assume that hyperhomocyst(e)inemia increases the release of fibrinogen into the plasma compartment. Taken together, increased production of both fibrinogen and thrombin (via inhibition of thrombomodulin and protein C) may lead to a thrombophilic situation in hyperhomocyst(e)inemia.
In conclusion, our data suggest that moderately elevated homocyst(e)ine levels represent a cardiovascular risk factor. In this study, this risk association was independent of most coronary risk factors except fibrinogen. This relation may indicate hypercoagulability as one mechanism by which homocyst(e)inemia increases coronary risk. Future studies may prove whether determination of fibrinogen and homocyst(e)ine levels could identify increased coronary risk in individuals who may be candidates for specific therapies.
